Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production.
about
Chemoprevention in familial adenomatous polyposisCyclooxygenase inhibition: between the devil and the deep blue seaAssessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tractCardiovascular hazard of selective COX-2 inhibitors: myth or reality?Apoptosis of human gastric cancer SGC-7901 cells induced by mitomycin combined with sulindac.COX-2 inhibitors compared and contrasted.Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor.Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors.Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects.Role of cyclooxygenase isoforms in gastric mucosal defense and ulcer healing.Gastric mucosal injury in systemic lupus erythematosus patients receiving pulse methylprednisolone therapyLower Gastrointestinal Bleeding due to Non-Steroid Anti-Inflammatory Drug-Induced Colopathy Case Report and Literature Review.Endoscopic evaluation of the gastro-duodenal tolerance of short-term analgesic treatment with 25 mg diclofenac-K liquid capsules.Non-steroidal anti-inflammatory drug, nabumetone, prevents indometacin-induced gastric damage via inhibition of neutrophil functions.Characterization of etoricoxib, a novel, selective COX-2 inhibitor.Corticosteroids therapy and peptic ulcer disease in nephrotic syndrome patients.
P2860
Q27023845-E03FF8B4-7DD1-42EA-8C0E-DCABF5EFB4BEQ28192790-FA04C2D8-1858-4ACD-9256-FF38C4658C60Q28196933-3AD52BDD-AE72-4474-B63D-00DE38DA8E5FQ28198746-F97A7F37-406D-4432-99B6-128F0505CBF5Q31156666-69F62B3E-1D13-4CA7-B7AA-CD5816AF2BB6Q34515513-A35C0040-CEE6-4952-908B-5E0AA4B81066Q34530950-7C00D281-4B2C-4A0D-BA43-D42FE8F4D0FCQ35083808-00815639-8225-44D4-82B9-35437E56530DQ35195182-8925C7AF-0BF7-4FE8-82C3-89BF861CBF48Q36301681-44E72ECC-68F1-4363-9D63-9B6DACD1699DQ37399457-C41646AC-6FC6-4CC0-9949-16C9FEE56F1BQ37708339-D96E0D3A-E538-4E7A-8C6B-C4B551131D0DQ39251183-8FCEB52A-121E-46B2-88FF-9C5CDD2E3A75Q44360907-CB4D8EF7-017A-4B17-89C5-2768D87BEC53Q44484802-31C22542-EFF9-40A7-B351-130C96B06AC0Q55084293-69A50EA6-DC9F-4692-BCC7-FE65598EF298
P2860
Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Rofecoxib, a COX-2 inhibitor, ...... osal prostaglandin production.
@ast
Rofecoxib, a COX-2 inhibitor, ...... osal prostaglandin production.
@en
type
label
Rofecoxib, a COX-2 inhibitor, ...... osal prostaglandin production.
@ast
Rofecoxib, a COX-2 inhibitor, ...... osal prostaglandin production.
@en
prefLabel
Rofecoxib, a COX-2 inhibitor, ...... osal prostaglandin production.
@ast
Rofecoxib, a COX-2 inhibitor, ...... osal prostaglandin production.
@en
P2093
P356
P1433
P1476
Rofecoxib, a COX-2 inhibitor, ...... osal prostaglandin production.
@en
P2093
Atherton CT
Garlick NM
Gottesdiener K
P304
P356
10.1053/GAST.2001.22432
P407
P577
2001-03-01T00:00:00Z